Overview

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

Status:
Not yet recruiting

Trial end date:
2031-02-01

Target enrollment:

Participant gender:

Summary

A Randomized, Placebo-Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2

Phase:

Phase 3

Details

Lead Sponsor:

University of Ulm

Collaborator:

Stichting Hemato-Oncologie voor Volwassenen Nederland

Treatments:

Venetoclax